ArticleInternational journal of antimicrobial agents2026
Human serum albumin and biological fluids reduce cefiderocol activity in carbapenem-resistant gram-negative bacteria.
Article in International journal of antimicrobial agents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Human serum albumin (HSA), the predominant plasma protein, influences bacterial physiology and antibiotic susceptibility. We previously showed that HSA exposure alters Acinetobacter baumannii transcriptional profiles, reducing biofilm formation and modulating the expression of β-lactam resistance genes, while decreasing cefiderocol (FDC) activity through downregulation of TonB-dependent receptors (TBDRs). Since FDC uptake relies on siderophore-mediated transport, we hypothesised that albumin's iron content could affect bacterial susceptibility to FDC. However, its effect on FDC activity across carbapenem-resistant Gram-negative pathogens remains underexplored. Here, we evaluated FDC bactericidal efficacy in the presence of physiological HSA concentrations and various human biological fluids against five different species of carbapenem-resistant strains. Time-kill assays revealed that HSA markedly attenuates FDC activity, permitting bacterial regrowth in species including A. baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, and Achromobacter xylosoxidans. Human fluids with high protein content similarly reduced FDC efficacy. Transcriptional analyses indicated downregulation of iron uptake genes, suggesting that albumin-mediated iron availability modulates siderophore-dependent drug uptake. These findings highlight the significant role of host proteins and fluid environments in modulating FDC activity, underscoring the need to consider such factors when interpreting susceptibility information and optimising treatment strategies for infections caused by carbapenem-resistant pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.